The Eradication of Hepatitis C Virus after Liver Transplantation Improved Liver Function and Maintained the Health-related Quality of Life

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-03-13 DOI:10.1016/j.transproceed.2025.02.040

Atsushi Takai , Yoshihide Ueda , Etsuro Hatano , Hiroshi Seno

{"title":"The Eradication of Hepatitis C Virus after Liver Transplantation Improved Liver Function and Maintained the Health-related Quality of Life","authors":"Atsushi Takai , Yoshihide Ueda , Etsuro Hatano , Hiroshi Seno","doi":"10.1016/j.transproceed.2025.02.040","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The outcomes of hepatitis C virus eradication and health-related quality of life in the patients treated with direct-acting antivirals (DAAs) after liver transplantation were examined.</div></div><div><h3>Methods</h3><div>Thirty-five patients with HCV infection treated with sofosbuvir/ledipasvir after liver transplantation were enrolled in the study. The achievement rate of sustained viral response (SVR), liver function and health-related quality of life based on Short-Form-36 version 2 were evaluated.</div></div><div><h3>Results</h3><div>All 35 patients achieved SVR and liver function was improved to a level comparable to that of non-transplanted cases by the DAA treatment. As to health-related quality of life, the scores of general health, vitality and mental health were comparable to Japanese national standard scores among 8 subscales of Short-Form-36 version 2.</div></div><div><h3>Conclusion</h3><div>HCV eradication after liver transplantation is useful for not only improving liver function but maintaining health-related quality of life.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 4","pages":"Pages 593-597"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134525001393","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The outcomes of hepatitis C virus eradication and health-related quality of life in the patients treated with direct-acting antivirals (DAAs) after liver transplantation were examined.

Methods

Thirty-five patients with HCV infection treated with sofosbuvir/ledipasvir after liver transplantation were enrolled in the study. The achievement rate of sustained viral response (SVR), liver function and health-related quality of life based on Short-Form-36 version 2 were evaluated.

Results

All 35 patients achieved SVR and liver function was improved to a level comparable to that of non-transplanted cases by the DAA treatment. As to health-related quality of life, the scores of general health, vitality and mental health were comparable to Japanese national standard scores among 8 subscales of Short-Form-36 version 2.

Conclusion

HCV eradication after liver transplantation is useful for not only improving liver function but maintaining health-related quality of life.

查看原文本刊更多论文

肝移植术后丙型肝炎病毒的根除改善了肝功能，维持了健康相关的生活质量。

背景：研究肝移植术后接受直接作用抗病毒药物（DAAs）治疗的丙型肝炎病毒根除和健康相关生活质量的结果。方法：选取肝移植术后接受索非布韦/来地帕韦治疗的35例HCV感染患者为研究对象。评估基于Short-Form-36 version 2的持续病毒反应（SVR）满意率、肝功能和健康相关生活质量。结果：35例患者经DAA治疗均达到SVR，肝功能改善水平与未移植患者相当。在与健康相关的生活质量方面，一般健康、活力和心理健康得分在short -36 version 2的8个分量表中与日本国家标准得分相当。结论：肝移植术后根除HCV不仅有助于改善肝功能，而且有助于维持健康相关的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.